In its second M&A deal under CEO Paul Hudson, Sanofi has agreed to acquire Principia Biopharma in exchange for US$3.68 B. The deal gives Sanofi access to Principia’s Tailored Covalency® technology platform as well as full control of PRN2246/SAR442168, a BTK inhibitor that was the subject of a November 2017 licensing agreement between the two companies. The original agreement covered the development of the PRN2246/SAR442168 in the central nervous system (CNS) field only but now with the acquisition, Sanofi is free to advance beyond this into other CNS diseases and therapy areas.